scholarly journals Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009)

2012 ◽  
Vol 18 (3) ◽  
pp. 253-259 ◽  
Author(s):  
S.P. Hawser ◽  
S.K. Bouchillon ◽  
C. Lascols ◽  
M. Hackel ◽  
D.J. Hoban ◽  
...  
2011 ◽  
Vol 55 (8) ◽  
pp. 3917-3921 ◽  
Author(s):  
Stephen P. Hawser ◽  
Samuel K. Bouchillon ◽  
Christine Lascols ◽  
Meredith Hackel ◽  
Daryl J. Hoban ◽  
...  

ABSTRACTA total of 2,841 clinical isolates ofKlebsiella pneumoniaefrom intra-abdominal infections worldwide were collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) during 2008 and 2009. Overall, 22.4% of isolates had extended-spectrum β-lactamases (ESBLs). The most active antibiotics among the 11 tested were imipenem, amikacin, and ertapenem, though even these, like all other comparators, were less consistently active against ESBL-positive isolates than against ESBL-negative isolates. Globally, 6.5% of isolates were ertapenem resistant based on the June 2010 clinical breakpoints published by the Clinical and Laboratory Standards Institute, with MICs of ≥1 μg/ml. Molecular characterization of 43 isolates with ertapenem MICs of ≥4 μg/ml showed that they variously produced CTX-M or SHV ESBLs combined with altered impermeability and/or had KPC (n= 28), OXA-48 (n= 3), or VIM (n= 1) carbapenemases. Further monitoring of ertapenem susceptibility and molecular characterization of ertapenem-resistant isolates are needed.


Apmis ◽  
2009 ◽  
Vol 117 (7) ◽  
pp. 526-536 ◽  
Author(s):  
UMAER NASEER ◽  
BJØRG HALDORSEN ◽  
STÅLE TOFTELAND ◽  
KRISTIN HEGSTAD ◽  
FLEMMING SCHEUTZ ◽  
...  

2010 ◽  
Vol 65 (8) ◽  
pp. 1828-1830 ◽  
Author(s):  
I. Montesinos ◽  
H. Rodriguez-Villalobos ◽  
R. De Mendonca ◽  
P. Bogaerts ◽  
A. Deplano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document